Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3038% below fair value
$3.70−0.63 (-14.55%)
Close on Nov 16, 2026Market cap $104.43MP/E –Yield –
Journey Medical price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Journey Medical's price to sales ratio was 1.7× on Nov 11, 2026, against 3.1× a year earlier. Over the last 5 years it ranged from 0.3× to 3.2×, with a median of 1.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.7× | −1.3 |
| 2025 | Dec 31, 2025 | 3.0× | +1.7 |
| 2024 | Dec 31, 2024 | 1.3× | −0.0 |
| 2023 | Dec 29, 2023 | 1.4× | +1.0 |
| 2022 | Dec 30, 2022 | 0.4× | +0.1 |
| 2021 | Dec 31, 2021 | 0.3× | – |
See a number that looks wrong?